• Essa Ajmi Alodeani College of Medicine, Aldawadmi, Shaqra University, Kingdom of Saudi, Arabia


Axillary, Botulinum toxins, Anesthesia, Hyperhidrosis


Objective: The uncontrollable and excessive sweating is basically a disorder called Hyperhydrosis. Sweating is essential for thermal regulation but significantly impacts on the emotional and professional life of the people suffering from this. The aim of the present investigation was to observe the effectiveness of botulinum toxin type A in               patients with hyperhidrosis, the incidence of the disease, duration of the results and possible adverse effects.

Methods: 27 patients with hyperhidrosis (axillary, palmar and axillary-palmar in combination) were treated with intradermal injection of botulinum toxin type A. Gender and racial compositions respectively was as follows; Male (n=17 or 63%): female (n=10 or 37%) and white (n=19 or 70%): black (n=8 or 30%). In the case of axillary hyperhidrosis, local infiltrative anesthesia with subcutaneous injections (Lidocaine 1% with adrenaline) dosed with 20-50 ml for 30-240 min duration was used while locoregional anesthesia (Lidocaine 1% without adrenaline) dosed with 2-5 ml was applied in the case of palmar hyperhidrosis. Diluted botulinum toxin was injected intradermally in an already anesthetized area. Each point was dosed with 2-4 U thus maximum total dose applied was 240 (60 x 4) for each anatomical region with hyperhidrosis (axillae and palm).

Results: Axillary-palmar clinical condition was found to be the most common incidence of the disease followed by alone axillary and isolated palmar hyperhidrosis. More than 50% drop in the quantity of the sweating was observed at the completion of one month. Relapse in 12 % cases was reported. 64% patients were found be symptom-free for 9 mo. Only one patient showed side minor and easily manageable ecchymosis at a few points of intradermal injection and bilateral paresthesia hands and fingers.

Conclusion: Botulinum toxin treatment is an effective, safe, and minimally invasive therapeutic treatment option, although it is costly. It helps enhances the quality of life of the patients and bring them out of stress, anxiety and emotional stress.

Keywords: Axillary, Botulinum toxins, Anaesthesia, Hyperhidrosis


Download data is not yet available.


Mahendiran S, Burkhart CN, Burkhart CG. Hyperhidrosis: a review of a medical condition. Open Dermatol J 2009;3:195-7.

Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr Ann Psychiatry Relat Discip 2000;37:25-31.

Lerer B, Jacobowitz J, Wahaba A. Personality features in essential hyperhidrosis. Int J Psychiatry Med 1981;10:59-67.

Naumann MK, Hamm H, Lowe NJ. Botox hyperhidrosis clinical study group. effect of botulinum toxin type a on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002;147:1218-26.

Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004;51:241-8.

Christophers E, Kruger G, Fitzpatrick TB, Eisen AZ, Wolff K. editors. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill; 1987. p. 465.

Solish N, Wang R, Murray CA. Evaluating the patient presenting with hyperhidrosis. Thoracic Surgery Clinics 2008;18:133-40.

Solish N, Benohanian A, Kowalski JW. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 2005;31:405-13.

Cina CS, Clase CM. The illness intrusiveness rating scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res 1999;8:693-8.

Shams K, Rzany BJ, Prescott LE, Musekiwa A. Interventions for excessive sweating of unknown cause (Protocol). Cochrane Database Systematic Rev 2011. Doi:10.1002/14651858. [Article in Press].

Vetrugno R, Liguori R, Cortelli P, Montagna P. Sympathetic skin response: basic mechanisms and clinical applications. Clin Autonomic Res 2003;13:256-70.

Togel B, Greve B, Raulin C. Current therapeutic strategies for hyperhidrosis: a review. Eur J Dermatol 2002;12:219-23.

Schlereth T, Dieterich M, Birklein F. Hyperhidrosis-causes and treatment of enhanced sweating. Deutsches Arzteblatt Int 2009;106:32-7.

Ro K, Cantor R, Lange K, Ahn S. Palmar hyperhidrosis: evidence of genetic transmission. J Vascular Surg 2000;35:382-6.

Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol 1989;20:713-26.

Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: A case-control study of 387 patients. J Am Acad Dermatol 2009;61:242-6.

Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K, Auff E. A randomized, double-blind, placebo-controlled trial of botulinum a toxin for severe axillary hyperhidrosis. Br J Dermatol 1999;140:677-80.

Champion RH. Disorders of sweat glands. Textb Dermatol; 1986. p. 1745-62.

Baumann L, Slezinger A, Halem M, Vujevich J, Mallin K, Charles C, Martin LK, et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of myobloc (botulinum toxin type b) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005;31:263-70.

Walling HW, Swick BL. Treatment options for hyperhidrosis. Am J Clin Dermatol 2011;12:285-95.

Dressler D, Saberi SA. Botulinum toxin: mechanism of action. Eur Neurol 2005;53:3-9.

Hagenah R, Benecke R, Wiegand H. Effects of type a botulinum toxin on the cholinergic transmission at spinal renshaw cells and on the inhibitory action at Ia inhibitory interneurons. Naunyn Schmiedebergs Arch Pharmacol 1977;299:267-72.

Swartling C, Farnstrand C, Abt G. Side effects of intradermal injections of botilinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. Eur J Neurol 2001; 8:451-6.

Fujita M, Mann T, Mann O. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmar-plantar hyperhidrosis. J Am Acad Dermatol 2001;45:587-9.

De Almeida ART, Kadunc BV, de Oliveira EMM. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg 2001;27:34-6.

Alexander G, Christian AM, Nowell S. Botulinum toxin for hyperhidrosis. Am J Clin Dermatol 2009;10:87-102.

Steiner D. Quantitative sweats test: iodine-starch and gravimetry, in hyperhidrosis and botulinum. Eds. Toxin AR, T Almeida, DM Hexsel; 2004. p. 59-61.

Hexsel D, Rodrigues TC, Soirefmann M, Zechmeister-Prado D. Recommendations for performing and evaluating the results of the minor test according to a sweating intensity visual scale. Dermatol Surg 2010;36:120-2.

Rohrich RJ, Janis JE, Fagien S, Stuzin JM. The cosmetic use of botulinum toxin. Plast Reconstr Surg 2003;112:177S-88S.

Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000;143:824-7.

Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998;24:1179-80.

Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998;24:1179-80.

Hankins CL, Strimling R, Rogers GS. Botulinum a toxin for glabellar wrinkles. Dose and Response. Dermatol Surg 1998;24:1181-3.

Earp NEDS, Marmur ES. The five D’s of botulinum toxin: doses, dilution, diffusion, duration, and dogma. J Cosmetic Laser Ther 2008;10:93-102.

Goldman A. Toxina botulínica na cirurgia plástica: indicações e experiências em 1200 áreas tratadas. Rev Bras Cir Plast 1999;14:21-30.

Goldman A. Treatment of axillary and palmar hyperhidrosis with botulinum toxin. Aesthetic Plast Surg 2000;24:280-2.

Young O, Neary P, Keaveny TV, Mehigan D, Sheehan S. Evaluation of the impact of endoscopic transthoracic sympathectomy on patients with palmar hyperhydrosis. Eur J Vasc Endovasc Surg 2003;26:673-6.

Loureiro MP, Roman N, Weigmann SC, Fontana A, Boscardim PB. Simpatectomia lombar retroperitoneoscópica para tratamento de hiperidrose plantar. Rev Col Bras Cir 2007;34:222-4.

Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol 2009;10:87-102.

Solomon BA, Hayman R. Botulinum toxin type a therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000;42:1026-9.

Lowe NJ, Yamauchi PS, Lask GP. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002;28:822-7.

Baron JA, Zloty DM. Bilateral type 1 complex regional pain syndrome after local nerve blocks for palmar hyperhidrosis. Dermatol Surg 2009;35:885-7.

Stanton HM. Complex regional pain syndrome. Anesthesiol Clin North Am 2003;21:733-44.



How to Cite

Alodeani, E. A. “BOTULINUM TOXIN TYPE A: AN EFFECTIVE, SAFE AND MINIMALLY INVASIVE TREATMENT OPTION OF AXILLARY AND PALMAR HYPERHIDROSIS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 7, July 2016, pp. 237-40,



Original Article(s)